- Home
- ENVB vs NVVE Comparison
ENVB vs NVVE Comparison
Compare ENVB & NVVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- NVVE
- Stock Information
- Founded
- ENVB 1994
- NVVE 1996
- Country
- ENVB United States
- NVVE United States
- Employees
- ENVB N/A
- NVVE N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- NVVE Oil Refining/Marketing
- Sector
- ENVB Health Care
- NVVE Energy
- Exchange
- ENVB Nasdaq
- NVVE Nasdaq
- Market Cap
- ENVB 3.3M
- NVVE 3.7M
- IPO Year
- ENVB N/A
- NVVE N/A
- Fundamental
- Price
- ENVB $1.36
- NVVE $2.45
- Analyst Decision
- ENVB
- NVVE
- Analyst Count
- ENVB 0
- NVVE 0
- Target Price
- ENVB N/A
- NVVE N/A
- AVG Volume (30 Days)
- ENVB 564.4K
- NVVE 924.1K
- Earning Date
- ENVB 03-25-2025
- NVVE 03-27-2025
- Dividend Yield
- ENVB N/A
- NVVE N/A
- EPS Growth
- ENVB N/A
- NVVE N/A
- EPS
- ENVB N/A
- NVVE N/A
- Revenue
- ENVB N/A
- NVVE $5,144,831.00
- Revenue This Year
- ENVB N/A
- NVVE $200.61
- Revenue Next Year
- ENVB N/A
- NVVE $109.43
- P/E Ratio
- ENVB N/A
- NVVE N/A
- Revenue Growth
- ENVB N/A
- NVVE N/A
- 52 Week Low
- ENVB $1.26
- NVVE $2.23
- 52 Week High
- ENVB $657.00
- NVVE $17.30
- Technical
- Relative Strength Index (RSI)
- ENVB 16.91
- NVVE 38.88
- Support Level
- ENVB $1.26
- NVVE $2.84
- Resistance Level
- ENVB $1.70
- NVVE $3.05
- Average True Range (ATR)
- ENVB 0.17
- NVVE 0.47
- MACD
- ENVB 2.34
- NVVE -0.04
- Stochastic Oscillator
- ENVB 12.20
- NVVE 8.83
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.